FOLFOX-A For Locally Advanced Pancreatic Cancer: A Phase II Brown University Oncology Research Group Trial

PHASE2CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

July 12, 2016

Primary Completion Date

December 18, 2019

Study Completion Date

March 16, 2022

Conditions
Locally Advanced Pancreatic CancerPancreatic Cancer
Interventions
DRUG

FOLFOXA

"Schema:~1 cycle = 14 days \*\*It will not be considered a deviation if a cycle or pre-cycle assessment must be adjusted to accommodate scheduling or holidays. Adjustment must be documented with reason to BrUOG\*\*~Abraxane ®: 150mg/m2 IV over 30 minutes, day 1 (administered first) every 14 days.~Oxaliplatin: 85mg/m2, IV over 2 hours, day 1 every 14 days Leucovorin: 400mg/m2, IV over 2 hours, day 1 every 14 days 5-FU infusion:1200mg/m2/day, as a continuous IV infusion over 2 days, day 1 and day 2 (for a total dose of 2400mg/m2 over 46 hours.)~* It is at the discretion of the treating physician to give Neulasta, 6 mg sq x 1 post treatment~* Antiemetics will be administered as per standard institutional policy."

Trial Locations (1)

02903/02906

Rhode Island Hospital and The Miriam Hospital, Providence

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

Rhode Island Hospital

OTHER

lead

Brown University

OTHER